EDAP TMS 향후 성장
Future 기준 점검 1/6
EDAP TMS은 연간 수입과 매출이 각각 34.4%와 13.6% 증가할 것으로 예상되고 EPS는 연간 37.1%만큼 증가할 것으로 예상됩니다.
핵심 정보
34.4%
이익 성장률
37.05%
EPS 성장률
| Medical Equipment 이익 성장 | 16.2% |
| 매출 성장률 | 13.6% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 17 May 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Apr 27
EDAP: Reaffirmed 2026 Revenue Guidance Will Support Refined Upside Thesis
Analysts have trimmed their price target on EDAP TMS by $4, citing updated assumptions around discount rates, revenue growth, and future P/E that refine their view of the company’s risk and earnings profile. Analyst Commentary Bullish analysts acknowledge the $4 trim to the price target as a recalibration to updated discount rate, revenue, and future P/E assumptions, rather than a change in their broader view of EDAP TMS.내러티브 업데이트 • Apr 12
EDAP: Revised Outlook Will Rely On 2026 Revenue Guidance Execution
Analysts have lowered their price target on EDAP TMS to $10.00 from $14.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lowering the price target to US$10.00 from US$14.00 reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations rather than a single headline event.
내러티브 업데이트 • Mar 29
EDAP: Longer Term Revenue Outlook Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to $6.83. The change reflects updated assumptions for discount rate, revenue growth, profit margin, and future P/E that are now more closely aligned with their current modeling for the business.
내러티브 업데이트 • Mar 14
EDAP: 2026 Segment Guidance Will Limit Upside Versus Current Pricing
Analysts have adjusted their price target on EDAP TMS to reflect updated assumptions for revenue growth, profit margins, discount rate and future P/E. This has led to a revised valuation framework that investors should watch closely against the current share price in dollar terms.내러티브 업데이트 • Feb 28
EDAP: 2026 Segment Guidance Will Constrain Future Share Price Upside
Analysts have lifted their EDAP TMS price target to reflect updated assumptions for a $2.50 fair value, a slightly higher discount rate, a shift from a 1.0% revenue decline to 20.8% growth expectations, a modestly stronger 13.40% profit margin outlook, and a lower forward P/E of about 11.6x. What's in the News EDAP TMS issued revenue guidance for 2026 for its HIFU business, with a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million.내러티브 업데이트 • Feb 14
EDAP: Flat Revenue Outlook And Higher P/E Assumptions Will Limit Upside
Analysts have raised their $ fair value estimate for EDAP TMS from $1.50 to $2.50, citing updated assumptions that include a lower discount rate, a revenue growth outlook that is closer to flat, slightly higher profit margins, and a higher future P/E multiple. What's in the News Issued 2026 revenue guidance for the HIFU business in a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million (company guidance).분석 기사 • Feb 03
EDAP TMS S.A. (NASDAQ:EDAP) Shares Fly 32% But Investors Aren't Buying For Growth
EDAP TMS S.A. ( NASDAQ:EDAP ) shares have continued their recent momentum with a 32% gain in the last month alone...내러티브 업데이트 • Jan 31
EDAP: HIFU Guidance And FDA Clearance Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to US$25.18 from US$26.39, citing updated assumptions for the discount rate, profit margin and future P/E, which leave their fair value view broadly unchanged. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million, also provided in euro terms as €43.0 million to €46.0 million and €19.0 million to €22.0 million respectively (company guidance).내러티브 업데이트 • Jan 17
EDAP: Future Guidance And FDA Clearance Will Support Bullish Upside
Analysts now see higher upside for EDAP TMS, lifting their fair value estimate from about US$5.77 to roughly US$6.83 as they factor in slightly different assumptions around discount rate, revenue growth, profit margins and future P/E levels. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million (Key Developments).분석 기사 • Dec 20
EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Right But Growth Is Lacking After Shares Rocket 32%
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders would be excited to see that the share price has had a great month, posting...분석 기사 • Dec 13
EDAP TMS (NASDAQ:EDAP) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...내러티브 업데이트 • Aug 29
CE Mark And Global Expansion Will Elevate HIFU Adoption
Despite a modest decline in consensus revenue growth forecasts, EDAP TMS’s sharply higher projected P/E multiple suggests increased investor optimism regarding future earnings quality or profitability, driving the analyst price target up from $5.75 to $14.00. What's in the News EDAP TMS raised its 2025 core HIFU business revenue growth guidance to 26%-34% year over year, up from the previous 16%-25% range.분석 기사 • Aug 19
There Is A Reason EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Undemanding
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a strong buy right now...분석 기사 • Jul 03
Is EDAP TMS (NASDAQ:EDAP) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • May 18
Improved Revenues Required Before EDAP TMS S.A. (NASDAQ:EDAP) Stock's 28% Jump Looks Justified
Those holding EDAP TMS S.A. ( NASDAQ:EDAP ) shares would be relieved that the share price has rebounded 28% in the last...
새로운 내러티브 • Apr 08
CE Mark And Global Expansion Will Elevate HIFU Adoption
New approvals and strategic collaborations enhance EDAP TMS's market opportunities, potentially driving future revenue growth and improving margins.분석 기사 • Apr 03
EDAP TMS S.A. (NASDAQ:EDAP) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 27...분석 기사 • Mar 15
Is EDAP TMS (NASDAQ:EDAP) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...분석 기사 • Dec 25
Potential Upside For EDAP TMS S.A. (NASDAQ:EDAP) Not Without Risk
With a price-to-sales (or "P/S") ratio of 1.2x EDAP TMS S.A. ( NASDAQ:EDAP ) may be sending very bullish signals at the...분석 기사 • Oct 24
Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Sep 07
Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 35...분석 기사 • Jul 24
Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right now...분석 기사 • Mar 22
There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump
Despite an already strong run, EDAP TMS S.A. ( NASDAQ:EDAP ) shares have been powering on, with a gain of 28% in the...분석 기사 • Mar 03
Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Jan 19
It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)
With a median price-to-sales (or "P/S") ratio of close to 3.2x in the Medical Equipment industry in the United States...분석 기사 • Aug 11
Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a sell right now...분석 기사 • Dec 19
Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?
Does the December share price for EDAP TMS S.A. ( NASDAQ:EDAP ) reflect what it's really worth? Today, we will estimate...분석 기사 • Nov 23
EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for EDAP TMS S.A.'s ( NASDAQ:EDAP ) stock hasn't moved much. We did...Seeking Alpha • Sep 22
EDAP TMS stock falls 7% aftermarket on proposed ADS offering
EDAP TMS (NASDAQ:EDAP) stock fell ~7% postmarket after the company said it commenced a public offering of its American depositary shares, each representing one ordinary share. There can be no assurance as to whether or when the proposed offering may be completed or the actual size or terms.Seeking Alpha • Aug 24
EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M
EDAP TMS S.A. press release (NASDAQ:EDAP): Q2 GAAP EPS of $0.06 beats by $0.09. Revenue of $14.97M (+20.3% Y/Y) beats by $1.35M. 79% growth in HIFU revenues for the first half of 2022 compared to same period in 2021 Strong cash position of $48.5 million as of June 30, 2022 Company to host Focal One Expert User Panel event in New York City on Thursday, September 29.Seeking Alpha • Aug 08
EDAP's Focal One Revenue Is Set To Accelerate
The placement of new Focal Ones got off to a good start this year and a filled-up pipeline is promising more, boosted by a big reimbursement improvement for Medicare. Reimbursement for Medicare patients' procedures almost doubled in July, significantly improving the economics for the Focal One. This should also speed up reimbursement from private payers and boost market acceptance. Most revenues still come from an exclusive distribution deal for the ExactVu with Exact Imaging, a clever move tiding the company over until reimbursement is improved. EDAP (EDAP) is a French medical device company that was known for its ESWL (extracorporeal shock wave lithotripsy) but it developed a HIFU (high-intensity focused ultrasound) robotic device, the Focal One, which is FDA approved for treating prostate cancer. HIFU works through soft tissue ablation through ultrasound, a minimally-invasive alternative for intermediate-risk prostate cancer and salvage treatment. The company got a bump in reimbursement, improving the attractiveness of the device, and there are still plenty of markets to pursue in the US and elsewhere. In the coming years, the Focal One could be approved for multiple additional indications while the company is also successfully selling the ExactVu from strategic partner Exact Imaging, which is actually responsible for most of its revenue. Growth There was, not surprisingly, a dip in the early quarters of the pandemic but apart from the last two quarters of 2021, growth has returned: Data by YCharts The most important growth vectors are: Placing more machines Increasing procedures Improving reimbursement Additional indications Placing more machines Q1 was a pretty good quarter for placing new machines, with four Focal One Robotic HIFU units sold, three of which were sold in the US at prestigious academic hospitals. Management argues that there is a growing pipeline, consisting of large academic hospitals but also increasingly community hospitals. Increasing the installed base also generates a tail of recurring revenues in the form of service contracts ($80K per year after year 1) and consumables (handpieces at $1800). They had a very successful presentation at the AUA, the American Urological Association, the largest annual gathering of neurologists worldwide where they showcased the Focal One and supported an accredited AUA course with hands-on training. Management argued they received additional interest as a result of the AUA. The company also sold nine ExactVu units (versus 5 in Q1/21), five of which were in the US, and one lithotripsy device for their legacy business (versus 6 in Q1/21). Increasing usage Management argued that the recently hired clinical sales managers had an immediate impact on usage within their existing customer base. They also engage in training programs for doctors to familiarize them with the Focal One. They didn't provide much detail on the CC about usage apart from noting that there was good usage momentum. Reimbursement The company does have a CPT (Current Procedural Terminology) code but management was disappointed when they were not bumped up to APC level 6, despite a unanimous conclusion from the advisory board. However, as expected, this all changed in July when the company finally achieved the APC level 6 code and this almost doubled the reimbursement from $4506 to $8711 (on average, there are slight variations determined by local wage levels) per procedure for Medicare patients. This not only increases the company's revenues from Medicare patients, it also furthers market adoption; from the company PR: The increase to APC level 6 has positive implications for patients beyond Medicare since many commercial payors have begun to cover focal HIFU for their members. Commercial payment and access policies are influenced by Medicare policy and reimbursement decisions. Additional indications Endometriosis BPH treatment Pancreatic cancer Liver cancer Breast cancer Endometriosis is furthest along as the company embarked on a (fairly small) P2 stage clinical trial which will end in September, with the first data expected before the end of the year. Other indications are further out. Financials From the 6-K: EDAP 6-K Results expressed in USD for Q2 will have some headwinds as the rate used in Q1 ($1.1177 euro per dollar) has come down considerably. Recurring revenues increased 17.5%, considerably less than the 44.4% rise in revenue from equipment. This isn't all that surprising as the newly sold devices do not earn any service revenue for the first year. Disaggregated revenue looks like this: EDAP 6-K It's quite remarkable that the distribution division is still by far the biggest revenue generator, this is the sales of the ExactVu, which is a device made by Exact Imaging, not EDAP. It's also the division that turns what would otherwise be an operating loss into an operating profit. That exclusive distribution deal is doing both companies wonders, no doubt about it. Margins Data by YCharts Since most of the sales come from the ExactVu, gross margins have suffered a bit since the start of 2021, but in the last two quarters, gross margins have recovered on economies of scale.분석 기사 • Jul 19
Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 89 | -22 | -28 | -23 | 2 |
| 12/31/2027 | 80 | -28 | -32 | -27 | 3 |
| 12/31/2026 | 75 | -34 | -39 | -35 | 3 |
| 3/31/2026 | 74 | -31 | -19 | -14 | N/A |
| 12/31/2025 | 71 | -29 | -22 | -16 | N/A |
| 9/30/2025 | 75 | -23 | -19 | -13 | N/A |
| 6/30/2025 | 74 | -25 | -21 | -15 | N/A |
| 3/31/2025 | 68 | -23 | -21 | -16 | N/A |
| 12/31/2024 | 69 | -21 | -19 | -15 | N/A |
| 9/30/2024 | 71 | -25 | -25 | -21 | N/A |
| 6/30/2024 | 66 | -21 | -21 | -17 | N/A |
| 3/31/2024 | 65 | -20 | -21 | -17 | N/A |
| 12/31/2023 | 67 | -23 | -21 | -16 | N/A |
| 9/30/2023 | 60 | -22 | -22 | -18 | N/A |
| 6/30/2023 | 62 | -19 | -18 | -14 | N/A |
| 3/31/2023 | 62 | -12 | -11 | -7 | N/A |
| 12/31/2022 | 59 | -3 | -6 | -3 | N/A |
| 9/30/2022 | 52 | 3 | 4 | 6 | N/A |
| 6/30/2022 | 53 | 3 | 3 | 5 | N/A |
| 3/31/2022 | 52 | 0 | 2 | 4 | N/A |
| 12/31/2021 | 50 | 1 | 3 | 5 | N/A |
| 9/30/2021 | 53 | 0 | 5 | 7 | N/A |
| 6/30/2021 | 54 | 0 | N/A | N/A | N/A |
| 3/31/2021 | 52 | 0 | N/A | N/A | N/A |
| 12/31/2020 | 51 | -2 | 0 | 2 | N/A |
| 9/30/2020 | 45 | -4 | N/A | N/A | N/A |
| 6/30/2020 | 44 | -2 | N/A | N/A | N/A |
| 3/31/2020 | 47 | 0 | N/A | N/A | N/A |
| 12/31/2019 | 50 | 2 | N/A | 4 | N/A |
| 9/30/2019 | 50 | 4 | N/A | N/A | N/A |
| 6/30/2019 | 50 | 2 | N/A | N/A | N/A |
| 3/31/2019 | 45 | 0 | N/A | N/A | N/A |
| 12/31/2018 | 45 | 0 | N/A | 0 | N/A |
| 9/30/2018 | 42 | -2 | N/A | N/A | N/A |
| 6/30/2018 | 41 | -2 | N/A | 0 | N/A |
| 3/31/2018 | 45 | -3 | N/A | N/A | N/A |
| 12/31/2017 | 43 | -1 | N/A | -4 | N/A |
| 9/30/2017 | 42 | -2 | N/A | N/A | N/A |
| 6/30/2017 | 42 | 0 | N/A | -4 | N/A |
| 3/31/2017 | 38 | 4 | N/A | N/A | N/A |
| 12/31/2016 | 37 | 4 | N/A | 1 | N/A |
| 9/30/2016 | 41 | 11 | N/A | N/A | N/A |
| 6/30/2016 | 39 | 5 | N/A | 4 | N/A |
| 3/31/2016 | 40 | 2 | N/A | N/A | N/A |
| 12/31/2015 | 35 | -2 | N/A | 1 | N/A |
| 9/30/2015 | 30 | -11 | N/A | N/A | N/A |
| 6/30/2015 | 30 | 2 | N/A | -2 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: EDAP 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: EDAP 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: EDAP 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: EDAP 의 수익(연간 13.6%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: EDAP 의 수익(연간 13.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: EDAP의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/18 00:32 |
| 종가 | 2026/05/18 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
EDAP TMS S.A.는 7명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| null null | CG Capital |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |